Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.61 | 50.99 | 46.37 | 50.12 | 48.36 | 40.22 | 49.04 | 53.38 | 62.60 | 62.94 | 69.63 | 56.80 |
| Expenses | 37.32 | 45.02 | 40.58 | 41.50 | 41.12 | 35.95 | 42.41 | 45.94 | 54.52 | 56.09 | 64.75 | 52.49 |
| Operating Profit | 5.29 | 5.97 | 5.79 | 8.62 | 7.24 | 4.27 | 6.63 | 7.44 | 8.08 | 6.85 | 4.88 | 4.31 |
| OPM % | 12.41% | 11.71% | 12.49% | 17.20% | 14.97% | 10.62% | 13.52% | 13.94% | 12.91% | 10.88% | 7.01% | 7.59% |
| Other Income | 0.22 | 0.10 | 0.25 | 0.11 | 0.95 | 0.19 | 0.43 | 0.18 | 0.63 | -0.17 | 1.76 | 0.15 |
| Interest | 1.43 | 1.35 | 1.41 | 1.50 | 1.38 | 1.23 | 1.28 | 1.22 | 1.40 | 1.47 | 1.61 | 1.64 |
| Depreciation | 1.74 | 1.78 | 1.84 | 1.83 | 1.94 | 1.79 | 1.83 | 1.94 | 2.10 | 1.96 | 2.04 | 2.22 |
| Profit before tax | 2.34 | 2.94 | 2.79 | 5.40 | 4.87 | 1.44 | 3.95 | 4.46 | 5.21 | 3.25 | 2.99 | 0.60 |
| Tax % | 20.09% | 25.85% | 19.35% | 26.30% | 29.77% | 16.67% | 26.08% | 26.46% | 30.33% | 16.62% | 27.09% | 28.33% |
| Net Profit | 1.87 | 2.18 | 2.24 | 3.99 | 3.42 | 1.21 | 2.93 | 3.28 | 3.62 | 2.71 | 2.19 | 0.43 |
| EPS in Rs | 1.63 | 1.90 | 1.95 | 3.47 | 2.97 | 1.05 | 2.54 | 2.85 | 3.16 | 2.36 | 1.90 | 0.37 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 71 | 95 | 106 | 109 | 95 | 90 | 163 | 168 | 189 | 188 | 249 | 252 |
| Expenses | 61 | 82 | 95 | 99 | 89 | 80 | 140 | 145 | 165 | 161 | 221 | 228 |
| Operating Profit | 10 | 13 | 10 | 10 | 6 | 10 | 23 | 23 | 24 | 27 | 27 | 24 |
| OPM % | 14% | 14% | 10% | 9% | 7% | 11% | 14% | 14% | 12% | 14% | 11% | 10% |
| Other Income | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 2 |
| Interest | 4 | 5 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 7 | 7 | 7 | 8 | 8 |
| Profit before tax | 3 | 5 | 3 | 5 | -2 | -0 | 12 | 12 | 12 | 16 | 16 | 12 |
| Tax % | 28% | 22% | 65% | 28% | 48% | 350% | 33% | 30% | 20% | 26% | 26% | |
| Net Profit | 3 | 4 | 1 | 3 | -3 | -0 | 8 | 9 | 10 | 12 | 12 | 9 |
| EPS in Rs | 2.95 | 4.33 | 1.23 | 3.88 | -3.42 | -0.42 | 8.40 | 7.51 | 8.37 | 10.03 | 10.26 | 7.79 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 13% | 23% | 14% | 32% | ||
| Compounded Profit Growth | 18% | 105% | 14% | -7% | ||
| Stock Price CAGR | 13% | 35% | 8% | -11% | ||
| Return on Equity | 11% | 15% | 15% | 14% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 11 | 11 | 11 | 11 |
| Reserves | 17 | 19 | 23 | 24 | 27 | 24 | 24 | 38 | 51 | 60 | 72 | 84 |
| Borrowings | 41 | 42 | 39 | 37 | 42 | 51 | 59 | 69 | 55 | 81 | 70 | 83 |
| Other Liabilities | 17 | 10 | 15 | 18 | 17 | 23 | 15 | 36 | 28 | 38 | 37 | 50 |
| Total Liabilities | 83 | 79 | 86 | 87 | 95 | 107 | 106 | 153 | 145 | 190 | 190 | 228 |
| Fixed Assets | 36 | 38 | 47 | 44 | 51 | 58 | 60 | 72 | 77 | 89 | 88 | 115 |
| CWIP | 1 | 2 | 0 | 0 | 0 | 3 | 5 | 3 | 2 | 21 | 29 | 11 |
| Investments | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 45 | 38 | 38 | 43 | 43 | 46 | 41 | 78 | 66 | 80 | 72 | 101 |
| Total Assets | 83 | 79 | 86 | 87 | 95 | 107 | 106 | 153 | 145 | 190 | 190 | 228 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -0 | 3 | 16 | 13 | 9 | 9 | 6 | 9 | 21 | 16 | 32 | 8 |
| Cash from Investing Activity | -4 | -6 | -10 | -5 | -11 | -13 | -7 | -16 | -10 | -32 | -16 | -16 |
| Cash from Financing Activity | 6 | 1 | -5 | -7 | 1 | 5 | 0 | 12 | -14 | 15 | -16 | 8 |
| Net Cash Flow | 1 | -2 | 0 | 1 | -1 | 0 | -0 | 4 | -3 | -1 | 0 | -0 |
| Free Cash Flow | -4 | -3 | 5 | 8 | -3 | -4 | -0 | -8 | 11 | -16 | 16 | -9 |
| CFO/OP | 15% | 46% | 134% | 134% | 99% | 153% | 71% | 38% | 103% | 79% | 130% | 42% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 84 | 100 | 72 | 65 | 64 | 88 | 68 | 85 | 61 | 63 | 60 | 56 |
| Inventory Days | 38 | 64 | 50 | 45 | 52 | 76 | 80 | 73 | 79 | 94 | 87 | 90 |
| Days Payable | 51 | 30 | 48 | 45 | 44 | 74 | 46 | 81 | 53 | 74 | 72 | 80 |
| Cash Conversion Cycle | 71 | 134 | 74 | 64 | 72 | 90 | 102 | 77 | 86 | 83 | 75 | 65 |
| Working Capital Days | 16 | 7 | -26 | -8 | 0 | -31 | -66 | -35 | -19 | -23 | -24 | -11 |
| ROCE % | 16% | 11% | 14% | 11% | 12% | 3% | 6% | 17% | 15% | 13% | 14% | 14% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% |
| Public | 27.69% | 27.70% | 27.70% | 27.70% | 27.71% | 27.71% | 27.70% | 27.70% | 27.71% | 27.70% | 27.71% | 27.71% |
| No. of Shareholders | 3,543 | 3,536 | 4,496 | 4,406 | 4,173 | 4,521 | 4,440 | 4,317 | 4,111 | 3,900 | 3,721 | 3,572 |
Fundamentals
Market Cap₹ 131 Cr.
Current Price₹ 114
Stock P/E13.0
Book Value₹ 82.8
ROCE13.9 %
ROE14.4 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)32%
Compounded Profit Growth (TTM)-7%
Consolidated figures.
Valuation
Market capRs 130 Cr
Enterprise valueRs 210 Cr
P/E (TTM)14.48x
Price to book1.36x
Price to sales0.51x
EV / EBITDA7.93x
EV / EBIT11.56x
EV / sales0.83x
Price to cash flow16.20x
Earnings yield6.91%
P/E, 3-year average13.07x
P/B, 3-year average1.78x
P/E, 5-year average12.19x
P/B, 5-year average1.80x
Profitability
Operating margin (excl. other income)10.96%
Operating margin (incl. other income)11.93%
EBITDA margin10.51%
Pre-tax margin4.78%
Net profit margin3.55%
Net margin, latest quarter0.76%
ROE13.22%
ROCE13.08%
ROA5.64%
ROE, 3-year average14.16%
ROCE, 3-year average13.27%
ROA, 3-year average5.81%
ROE, 5-year average15.71%
ROCE, 5-year average14.26%
ROA, 5-year average5.91%
ROIC (approx.)7.68%
Tax rate25.79%
Other income / net worth2.53%
Growth
Sales growth (latest year)32.39%
Profit growth (latest year)2.26%
Sales CAGR, 3 years14.03%
Sales CAGR, 5 years22.51%
Profit CAGR, 3 years10.97%
Sales growth QoQ-18.43%
Profit growth QoQ-80.28%
Sales growth YoY (latest quarter)6.41%
Profit growth YoY (latest quarter)-86.85%
Per share
EPS (TTM)Rs 7.81
EPS (latest quarter)Rs 0.38
EPS, 3-year averageRs 9.20
EPS, 5-year averageRs 8.57
Book value per shareRs 83.07
Sales per shareRs 220.01
Cash flow per shareRs 6.99
Free cash flow per shareRs -7.86
Efficiency
Asset turnover1.09x
Fixed asset turnover2.17x
Inventory turnover4.06x
Inventory days90 days
Debtor days56 days
Debtors turnover6.57x
Creditor days80 days
Cash conversion cycle65 days
Working capital days-11 days
Leverage
Total debtRs 83 Cr
Cash and bankRs 2 Cr
Net debtRs 81 Cr
Debt to equity0.87x
Net debt / EBITDA3.04x
Interest coverage2.97x
Owners' fund to total sources41.80%
Debt to assets36.37%
Cash flow
Cash from Operating Activity (latest year)Rs 8 Cr
Cash from Investing Activity (latest year)Rs -16 Cr
Cash from Financing Activity (latest year)Rs 8 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs -9 Cr
FCFE (approx.: FCF + change in debt)Rs 4 Cr
Cash from ops / profit, 5 years1.69x
Sales to cash flow31.07x
Statement figures
Net sales (TTM)Rs 252 Cr
Net sales (latest year)Rs 249 Cr
Sales (latest quarter)Rs 57 Cr
Operating profit excl. other income (latest year)Rs 27 Cr
Operating profit (latest quarter)Rs 4 Cr
Other income (TTM)Rs 2 Cr
EBITDA (TTM)Rs 26 Cr
PBDT (TTM)Rs 20 Cr
Profit before tax (TTM)Rs 12 Cr
Tax (latest year)Rs 4 Cr
Net profit (TTM)Rs 9 Cr
Net profit (latest year)Rs 12 Cr
Net profit (latest quarter)Rs 0 Cr
Depreciation (TTM)Rs 8 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 6 Cr
Cost of goods sold (latest year)Rs 147 Cr
Total expenditure (latest year)Rs 221 Cr
Total income (latest year)Rs 251 Cr
Share capitalRs 11 Cr
ReservesRs 84 Cr
Shareholders' fundsRs 95 Cr
Total assetsRs 228 Cr
Net blockRs 115 Cr
Capital work in progressRs 11 Cr
InvestmentsRs 0 Cr
ReceivablesRs 38 Cr
InventoryRs 36 Cr
Other liabilitiesRs 50 Cr
Shares outstanding (crore)1.15
Ownership
Promoter holding72.30% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 14.5 is at the 63th percentile of its own 7.4-year range
(median 13.0, low 4.5, high 51.5).
P/B 1.37 is at the 35th percentile (median 1.63).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | PARNAXLAB | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -8.7% | -2.8% | -5.9 pts |
| 1 month | -19.6% | -6.8% | -12.8 pts |
| 3 years | +27.1% | +14.2% | +13.0 pts |
| 5 years | +355.3% | +27.9% | +327.4 pts |
Red flags
F-score 5 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹57 Cr +6.4% vs Jun 2025.
Net profit ₹0 Cr -86.9%.
Against our estimate for Jun 2026: sales -28.7%, profit -89.3% big miss. Our estimate for Sep 2026: sales Rs 78 Cr, profit Rs 3 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Less than 100 unique PAN traded in previous 30 days
Quick answers
What is the market cap of Parnax Lab Ltd?
Parnax Lab Ltd (PARNAXLAB) has a market capitalisation of Rs 131 Cr. at the 2026-10-01 close.
What is the P/E ratio of Parnax Lab Ltd?
Parnax Lab Ltd trades at a P/E of 13.0 on trailing twelve-month profit, at the 2026-10-01 close.
What were Parnax Lab Ltd's latest quarterly results?
In the Jun 2026 quarter, Parnax Lab Ltd sales was Rs 57 Cr (+6.4% vs Jun 2025) and net profit was Rs 0 Cr.
What is the 52-week high and low of Parnax Lab Ltd?
The 52-week high is Rs 149.50 and the 52-week low is Rs 104.00.